In this regard, inhibitors of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) enzymes involved in the degradation of essential neurotransmitter acetylcholine (ACh) represent major compounds approved for clinical use in the symptomatic management of AD. Here, BCHE is linked to Alzheimer disease.